Client: Top 10 Pharma Company.
An international Pharma company BD groups wanted to conduct an R&D asset prioritization exercise, to guide strategic in-licensing initiatives in the oncology space. Specifically in Oncology.
Our Solution
- In clinical development – Phases I, II and III
- Within eight indications; GBM (Multiform Glioblastoma), Ovarian Gastric/GEJ, NSCLC, CRC, Bladder, RCC, TN Breast Cancer.
Outcome
- GlobalData built an interactive, custom prioritization tool to readily short list the assets.
- GD identified 5 assets that the BD team had not considered in the past and the company moved those opps further through DD.
- GD is now on retainer to this company to support asset identification and prioritization.
Our consultants work closely with you to understand requirements and develop a tailored approach and deliverables.
